The oxidative stress is considered to be involved in the pathophysiology of cancers. In the current study we explored the oxidative stress in patients with different cancers and corresponding benign diseases by evaluation of the level of lipid peroxidation products (MDA level) in the plasma and the activity of erythrocyte antioxidant defense enzymes superoxide dismutase (SOD) and catalase (CAT). Significantly higher plasma levels of lipid peroxidation products were detected in patients with early and advanced cancers in comparison to the healthy volunteers (mean 3.1 micromol/l and 2.3 micromol/l, p = 0.0003 and p = 0.029, respectively, t-test). In addition, 10-20 days after radical operations of cancer patients with normal postoperative recovery period, the plasma levels of MDA decreased and reached values close to the controls (mean 2.0 micromol/l). SOD in erythrocytes of patients with benign diseases and malignant solid tumors before and after surgery did not differ from that of the controls. In contrast, CAT activity of patients with early cancers was found to be significant higher than that of the controls (mean 22157.2 U/gHb vs. 12832.0 U/gHb, p = 0.032, t-test). A decrease of CAT activity was observed after surgery (mean 15225.0 U/gHb). In conclusion, our results suggest the presence of an increased oxidative stress accompanied by a lack of changes of erythrocyte SOD activity and an adaptive increase of CAT activity.

Background SGI-110 is second generation HMA formulated as a dinucleotide of decitabine (DAC) and deoxyguanosine delivered as a small volume, pharmaceutically stable SQ injection allowing longer half-life and more extended decitabine exposure than DAC IV infusion. SGI-110 differentiated pharmacokinetic profile resulted in potent hypomethylation and clinical responses in previously treated MDS and AML patients in the phase 1 trial (Kantarjian et al. 2012). Methods In a randomized Phase 2 study, relapsed/refractory AML, or elderly treatment naïve AML patients who were not suitable for induction chemotherapy (poor major organ function; poor cytogenetics; or secondary AML) were randomized to one of two SQ doses – the biologically effective dose (BED) of 60 mg/m2 QDx5 or 90 mg/m2 QDx5. The primary endpoint of the phase 2 study is the overall remission rate (CR, CRi, and CRp) based on the International Working Group Criteria 2003. Safety findings based on adverse events (AEs) as graded by the CTCAE v4 criteria and pharmacodynamic data on Long Interspersed Nucleotide Element (LINE-1) DNA methylation (an index of global DNA methylation) activity were also assessed and reported. Results As of June 30, 2013, sixty-seven patients (50 relapsed/refractory AML, 17 treatment naïve elderly AML) were treated and had a minimum follow up of 3 months. Patients were randomized to either 60 mg/m2 dose (32 patients) or 90 mg/m2 dose (35 patients). The median age was 66 years (range, 22–84), 69% were male, and ECOG PS of 0/1/2 was reported in 11/47/9 patients respectively. Median number of prior regimens was 2 (range, 0–10). Patients’ characteristics were well balanced between the 2 dose groups. The primary endpoint of overall remissions (CR, CRp, or CRi) was observed in 17/67 patients (25% with 95% CI, 16–37%). There were 8 complete remissions (CR, CRp, or CRi) in 50 patients with relapsed/refractory AML (16% with 95% CI, 7-29%); and 9 complete remissions (CR, CRp, or CRi) in 17 treatment-naïve elderly AML patients (53% with 95% CI, 28-77%). Five patients (4 relapsed/refractory, and one treatment-naïve elderly AML) subsequently received a stem cell transplant. There was no difference in the complete remission rate between 60 and 90 mg/m2 doses (8 remissions in 32 patients at 60 mg/m2, and 9 remissions in 35 patients at 90 mg/m2). LINE-1 DNA methylation data before and after treatment was available in 50 (75%) patients enrolled. LINE-1 demethylation ≥ 10% post treatment was observed in 83% and 78% in the 60 mg/m2 and 90 mg/m2, respectively. The median maximum LINE-1 demethylation for responders is 25% as compared to 19% for non-responders. The most common adverse events (AEs) regardless of relationship to SGI-110 ≥ Grade 3 include febrile neutropenia, thrombocytopenia, anemia, leukopenia, neutropenia, and pneumonia. The 90 mg/m2 dose showed a greater frequency of Grade 3/4 related AEs ≥ 10% (anemia, febrile neutropenia, leukopenia, neutropenia, and thrombocytopenia) compared to the 60 mg/m2 dose. Conclusions SQ SGI-110 is a new HMA which is well tolerated and clinically active in the treatment of AML. Complete remissions and potent demethylation of ≥10% were equally observed at the 2 dose groups of 60 and 90 mg/m2. These data support further phase 3 investigation of this agent in the treatment of AML. Preliminary overall remission rate of 53% in treatment-naïve elderly AML seems to compare favorably with previous results reported for HMA treatment but this needs to be confirmed in a larger number of patients and randomized studies. Disclosures: Kantarjian: Astex Pharmaceuticals, Inc.: Research Funding. Jabbour:Astex Pharmaceuticals, Inc.: Research Funding. Yee:Astex Pharmaceuticals, Inc.: Research Funding. Kropf:Astex Pharmaceuticals, Inc.: Research Funding. O'Connell:Astex Pharmaceuticals, Inc.: Research Funding. Stock:Astex Pharmaceuticals, Inc.: Research Funding. Tibes:Astex Pharmaceuticals, Inc.: Research Funding. Rizzieri:Astex Pharmaceuticals, Inc.: Research Funding. Walsh:Astex Pharmaceuticals, Inc.: Research Funding. Griffiths:Astex Pharmaceuticals, Inc.: Research Funding. Roboz:Astex Pharmaceuticals, Inc.: Honoraria, Research Funding. Savona:Astex Pharmaceuticals, Inc.: Research Funding. Ervin:Astex Pharmaceuticals, Inc.: Research Funding. Podoltsev:Astex Pharmaceuticals, Inc.: Research Funding. Pemmaraju:Astex Pharmaceuticals, Inc.: Research Funding. Daver:Astex Pharmaceuticals, Inc.: Research Funding. Garcia-Manero:Astex Pharmaceuticals, Inc.: Research Funding. Borthakur:Astex Pharmaceuticals, Inc.: Research Funding. Wierda:Astex Pharmaceuticals, Inc.: Research Funding. Ravandi:Astex Pharmaceuticals, Inc.: Research Funding. Cortes:Astex Pharmaceuticals, Inc.: Research Funding. Brandwein:Astex Pharmaceuticals, Inc.: Research Funding. Odenike:Astex Pharmaceuticals, Inc.: Research Funding. Feldman:Astex Pharmaceuticals, Inc.: Research Funding. Chung:Astex Pharmaceuticals Inc.: Research Funding. Naim:Astex Pharmaceuticals, Inc.: Employment. Choy:Astex Pharmaceuticals, Inc.: Employment. Taverna:Astex Pharmaceuticals, Inc.: Employment. Hao:Astex Pharmaceuticals Inc.: Employment. Dimitrov:Astex Pharmaceuticals, Inc.: Employment. Azab:Astex Pharmaceuticals, Inc.: Employment. Issa:Astex Pharmaceuticals, Inc.: Consultancy, Research Funding.

For decades now breast cancer tissue resection has been the primary method of choice for treating the disease, however this was not the case throughout the history of medicine. For centuries breast cancer was considered to be incurable via surgical approaches and that only early, low grade, lesions can be removed safely. Not until the 19 th century, an increase in primary surgical therapy for the disease (mainly radical mastectomies) was becoming evident due to the teachings of Morgagni, in addition to a complete re-conceivement of the etiological process of the disease by Le Dran. Currently, practitioners have achieved a very high level of proficiency in treating the disease via continuous refinement of the aforementioned facts. This resulted in tissue and organ sparing local surgical approaches, including wide local excisions through para-areolar incisions and even skin and nipple-sparing mastectomies, which have long overpassed the unnecessary and primitive high morbidity approaches performed in the earlier attempts to treat breast cancer. KEYWORDS breast surgery techniques, breast cancer treatment, breast history Early history of breast cancer Currently, breast cancer (BC) surgical excision remains the gold standard for treating the disease and due to its significant social and economic impact, researchers and clinicians have attempted to identify the pathogenic processes giving rise to the disease. However it took centuries for medical practitioners to reach these conclusions. Nonetheless, even throughout the ages breast cancer has been capturing the attention of medicine and surgery practitioners universally, with the Smith Surgical Papyrus (3000-2500 b.c.

The first in a series of reviews discusses the literature published so far relating to breast cancer including: epidemiology of the disease, economic impact, pathology of breast cancer as it remains the most common cancer diagnosed in women, the main molecular mechanisms of tumorigenesis accepted today, the invasion & metastasis cascade and the concerning relationship between benign and malignant disease. KEYWORDS breast cancer; breast disease; breast cancer impact EpidemiologyBreast cancer is the most common occurring malignancy in women of the developed world, comprising almost a third of all malignancies in females. It is defined as a malignant proliferation of the epithelial cells from which the breast ducts and milk-producing lobules constitute. The latest Western European statistics have shown that on average about 100,000 incidents of invasive breast carcinoma and, though slowly declining, 25,000 deaths due to the subsequent late stage metastatic spread occur annually (European region) [1]. On the other hand the incidents of the disease in eastern European countries were found to be somewhat lower, though still demonstrating a significant mortality factor [2], and unfortunately as the research shows there has been no significant improvement in breast cancer morbidity rates in that region.Globally, the lifetime risk of a woman developing invasive breast cancer is 13%, Meaning that one out of eight females will develop breast cancer at some point in their life [4]. The mortality rates have been shown to be highest in the ancient (>75

Traditionally, mammographic density (MD) of the breast has been assessed by a radiologist visually. This subjective evaluation requires significant experience to distinguish the relative proportions of the fibrous connective tissue and adipose tissue in the mammary gland correctly. The aim of this study is to compare the capabilities of the different methods (visual and computer-assisted) for assessing mammographic density. Our sample in this study consists of 66 patients with digital mammography. The mammographic density has been evaluated using the four-grade scale of the American College of Radiology (ACR); visually, visually using an analog scale and semi-automated using UTHSCSA Image Tool 3.0, Image J and Adobe Photoshop CS6 software. The average mammographic density calculated using the different methods is as follows: 34.8% (from 10% to 70%); 32.1%